Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

被引：0
作者：
Michael Guger
Christian Enzinger
Fritz Leutmezer
Franziska Di Pauli
Jörg Kraus
Stefan Kalcher
Erich Kvas
Thomas Berger
机构：
[1] Kepler University Hospital GmbH,Clinic for Neurology 2, Med Campus III
[2] Johannes Kepler University Linz,Medical Faculty
[3] Medical University of Graz,Department of Neurology
[4] Medical University of Vienna,Department of Neurology
[5] Medical University of Innsbruck,Clinical Department of Neurology
[6] Paracelsus Medical University and Salzburger Landeskliniken,Department of Laboratory Medicine
[7] Heinrich-Heine-University,Department of Neurology, Medical Faculty
[8] Hermesoft,undefined
[9] Data management,undefined
[10] Hermesoft,undefined
[11] Statistics,undefined
来源：
Journal of Neurology | 2021年 / 268卷
关键词：
Disability progression; Long-term; Multiple sclerosis; Natalizumab; Predictor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4303 / 4310
页数：7
相关论文
共 50 条
  • [41] Long-term experience with induction treatment regimens in multiple sclerosis
    Le Page, Emmanuette
    Edan, Gilles
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 277 : S46 - S49
  • [42] Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
    Tanasescu, Radu
    Frakich, Nanci
    Chou, I. -Jun
    Filippini, Perla
    Podda, Giulio
    Xin, Gao
    Muraleedharan, Ranjithmenon
    Jerca, Oltita
    Onion, David
    Constantinescu, Cris S.
    NEUROLOGY AND THERAPY, 2023, 12 (06) : 2041 - 2052
  • [43] Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
    Radu Tanasescu
    Nanci Frakich
    I.-Jun Chou
    Perla Filippini
    Giulio Podda
    Gao Xin
    Ranjithmenon Muraleedharan
    Oltita Jerca
    David Onion
    Cris S. Constantinescu
    Neurology and Therapy, 2023, 12 : 2041 - 2052
  • [44] Long-term efficacy of ocrelizumab in the treatment of patients with multiple sclerosis - case reports
    Krzystanek, Ewa
    Brola, Waldemar
    Wnuk, Marcin
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 93 - 104
  • [45] Long-term outcome of minocycline in relapsing-remitting multiple sclerosis
    Zhang, Y.
    Metz, L. M.
    Yong, V. W.
    Bell, R. B.
    Yeung, M.
    Patry, D.
    Mitchel, J. R.
    MULTIPLE SCLEROSIS, 2007, 13 (09): : 1226 - 1226
  • [46] Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis
    Rocco Totaro
    C. Di Carmine
    A. Splendiani
    S. Torlone
    L. Patriarca
    C. Carrocci
    S. Sciamanna
    C. Marini
    A. Carolei
    Neurological Sciences, 2016, 37 : 1113 - 1117
  • [47] Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies
    Rensel, Mary
    CHILDREN-BASEL, 2019, 6 (06):
  • [48] Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion
    Meuth, Sven G.
    Bayas, Antonios
    Kallmann, Boris
    Kleinschnitz, Christoph
    Linker, Ralf
    Rieckmann, Peter
    Maeurer, Mathias
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (16) : 1965 - 1969
  • [49] Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
    Ziemssen, Tjalf
    Thomas, Katja
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2017, 10 (10) : 343 - 359
  • [50] Long- term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
    Foley, John F.
    Nair, Kavita V.
    Vollmer, Timothy
    Stephenson, Judith J.
    Niecko, Timothy
    Agarwal, Sonalee S.
    Watson, Crystal
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 1035 - 1048
12345